Faculty introduction, disclosures
Introduction content: cursory refresher and review Epidemiology: statistics by severity, current trends, and associated healthcare costs Causes and risk factors Pathogenesis, including biochemical pathways and their effects on the cell life cycle Clinical features, presentation, and histopathology Updates in diagnosis Staging, comorbidities, and complications
TN MBC treatment Goals of therapy Therapy BRCA-associated disease: PARP inhibitors, platinum agents Cytotoxic chemotherapy Emerging therapies Epithelial growth factor inhibitors Angiogenesis inhibitors PARP inhibitors Immunotherapy Safety profiles of present and emerging agents Emerging models of care Challenges and barriers to care Patient case(s)
Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Describe the prognostic and treatment implications of TN status in the diagnosis and treatment of MBC.
• Describe treatment options presently available for TN MBC, including safety, and apply them to patient cases using evidence-based medicine.
• Describe emerging treatment options presently available for TN MBC, their mechanisms of action and safety, and anticipated place in therapy.
• Discuss barriers patients with TN MBC experience in attempting to access care, including burden of disease and adverse consequences of therapy, and propose ways to ameliorate them.

ACCME Activity #0

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Kevin Kalinsky, MD, MS, Herbert Irving Associate Professor of Medicine, Columbia University Irving Medical Center, has no relevant financial discloses.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME,  has no relevant financial discloses.

Commercial Support Disclosure: This program is supported by an educational grant from Eisai.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

*Required to view Printable PDF Version